偏远地区快速识别:BIOFIRE FilmArray BCID2诊断血流感染的性能与时效性
该回顾性观察研究评估了BIOFIRE FilmArray BCID2核酸扩增检测在澳大利亚北部两个偏远医院实验室中对阳性血培养液的性能和时效性。共回顾343份血培养,鉴定出366株病原体。BCID2在90.8%(207/228)含至少一种病原体的血培养中检测到临床显著病原体,与常规鉴定方法的一致性为98.3%(95%CI 96.1%-99.4%),且BCID2检测结果比常规鉴定中位提前2.8天。
要点
- BCID2在90.8%含病原体的血培养中检出临床显著病原体,与常规方法一致性达98.3%。
- BCID2检测结果较常规鉴定中位提前2.8天(IQR 2.0-3.1天)。
- 需增加BCID2未覆盖的靶标,如伯克霍尔德菌和常见污染菌。
核心结论
- BCID2在偏远地区医院实验室由普通科学家操作表现良好,显著提高了血流病原体鉴定的时效性。
- 需补充伯克霍尔德菌和常见污染菌等靶标。
研究设计与样本
- 回顾性观察研究,纳入2021年1月至2024年8月澳大利亚北领地两家偏远医院实验室的343份血培养,鉴定出366株病原体,与中心实验室常规鉴定比较。
主要发现
- BCID2在207/228(90.8%)含至少一种病原体的血培养中检出临床显著病原体。
- BCID2与常规鉴定方法对面板内病原体的一致性为98.3%(95%CI 96.1%-99.4%)。
- 126株 considered 污染菌,其中71株(56%)被BCID2检出。
- BCID2检测结果比常规鉴定中位提前2.8天(IQR 2.0-3.1天)。
临床怎么用
- 在偏远地区实验室可使用BCID2快速检测阳性血培养液,提前获得病原体鉴定结果。
- 需注意BCID2面板未覆盖伯克霍尔德菌等病原体,必要时补充检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bloodstream infection is a time-critical diagnosis; however, the vast geographic distances in rural and remote locations lead to prolonged specimen transport times, which can impact the timeliness and quality of results. In this retrospective observational study, we evaluated the performance and timeliness of the BIOFIRE FilmArray Blood Culture Identification 2 (BCID2) nucleic acid amplification test conducted on positive blood culture broth fluid in two very remote hospital laboratories in the Northern Territory, Australia, and compared the results to conventional testing done in central laboratories in the laboratory network. We reviewed 343 blood cultures, from which 366 organisms were identified, collected between January 2021 and August 2024. In 207/228 (90.8%) blood cultures with at least one pathogen, the clinically significant organism(s) were detected by BCID2. Concordance between BCID2 and conventional identification methods for organisms on the BCID2 panel was 98.3% (95% confidence interval 96.1%-99.4%). Seventy-four organisms isolated had no BCID2 target; of these, 21 were pathogens, 15 of which were Burkholderia pseudomallei. A total of 126 organisms were considered contaminants; 71 (56%) of these were detected by BCID2. Importantly, BCID2 detections preceded conventional identification results by a median of 2.8 days (interquartile range 2.0-3.1 days). The BCID2 panel performed well in the hands of general scientists and substantially improved the timeliness of bloodstream pathogen identification in our setting. The need for additional targets, including B. pseudomallei and common contaminants, was identified.IMPORTANCEBloodstream infection is a life-threatening condition requiring urgent treatment, and blood cultures are the mainstay of diagnosis. Timely incubation and processing of blood cultures maximize yield and clinical utility; however, prolonged specimen transport times in rural areas can impact the quality of results. We investigated the performance and timeliness of a rapid multiplex nucleic acid amplification test (the Blood Culture Identification 2 [BCID2] panel) for detection of bacteria and yeasts in positive blood culture broth fluid in two small remote Australian hospital laboratories. Formal organism identification and susceptibility testing were subsequently conducted in larger, central laboratories. We found that the BCID2 panel detected the clinically significant organism(s) in 90.8% of blood cultures with at least one pathogen, with 98.3% concordance between BCID2 and conventional identification methods for organisms on the panel. BCID2 detections preceded conventional identification by a median of 2.8 days. The assay substantially improved the timeliness of bloodstream pathogen identification in the two remote regions.
引用
- Simsic B, Ewin T, Hennessy J, et al. Remote regions, rapid recognition: performance and timeliness of BIOFIRE FilmArray BCID2 for diagnosing bloodstream infection in remote northern Australia. J Clin Microbiol. 2026. PMID: 42283523. doi:10.1128/jcm.00311-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。